Real-world evidence of safety and influence for lung cancer surgery under COVID-19 pandemic in Japan

被引:3
|
作者
Kato, Taketo [1 ]
Katsuya, Ryotaro [1 ]
Okado, Shoji [1 ]
Sato, Keiyu [1 ]
Noritake, Osamu [1 ]
Nakanishi, Keita [1 ]
Noguchi, Misa [1 ]
Kadomatsu, Yuka [1 ]
Ueno, Harushi [1 ]
Ozeki, Naoki [1 ]
Nakamura, Shota [1 ]
Fukumoto, Koichi [1 ]
Chen-Yoshikawa, Toyofumi Fengshi [1 ,2 ]
机构
[1] Nagoya Univ, Dept Thorac Surg, Grad Sch Med, Nagoya, Japan
[2] Nagoya Univ, Dept Thorac Surg, Grad Sch Med, 65 Tsurumai cho,Showa ku, Nagoya 4668550, Japan
关键词
COVID-19; pandemic; lung cancer surgery; tumor enlargement; short-term outcome; IMPACT; DIAGNOSIS; OUTCOMES; LOBECTOMY; DELAYS; UK;
D O I
10.21037/jtd-22-1289
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: The COVID-19 pandemic has affected the clinical practice of lung cancer surgery in Japan, but few studies have revealed the real situation of surgical practice for lung cancer in this country. This latest information will help us to decide the future direction of lung cancer surgery under pandemic circumstances.Methods: We collected data from patients with primary lung cancer who underwent thoracic surgery between 2018 and 2021. To investigate the impact of the COVID-19 pandemic on lung cancer surgery, we compared between 2018-2019 (prepandemic group) and 2020-2021 (pandemic group) in the respect of patient characteristics, pathological findings, and short-term outcome after lung cancer resection by Mann-Whitney and Fisher's exact tests. Moreover, the monthly number of surgeries for lung cancer in our institution during 2020-2021 was compared with the number of newly diagnosed COVID-19 patients in Japan by Spearman correlation analysis.Results: From 2018 through 2021, 936 patients with primary lung cancer underwent surgical intervention in our institute and were included in this study. The number of surgeries did not decrease in the pandemic group (n=443) compared with that in the prepandemic group (n=493). Tumor and invasive size in stage I which was measured by pathologist were significantly larger in the pandemic group than in the prepandemic group (tumor size: P=0.031, invasive size: P<0.001). In terms of postoperative short-term outcome, the median hospital stay was 6 days, 30-day mortality was 2, and morbidity was around 20% in both groups. Only one patient suffered from COVID-19 infection 5 months after right upper lobectomy. An increased ratio of newly diagnosed COVID-19 cases in Japan was negatively correlated with the number of surgeries for lung cancer in our institution in the next month (r=-0.393, P=0.007), although there was no correlation in the present or the month after next.Conclusions: Even during the COVID-19 pandemic period, lung cancer surgery could be performed safely and in a sustainable manner. However, pathological findings of lung cancer tended to be progressive in early-stage lung cancer.
引用
收藏
页码:542 / +
页数:12
相关论文
共 50 条
  • [31] Real-World Safety and Effectiveness of Remdesivir and Corticosteroids in Hospitalized Patients with COVID-19
    Caffrey, Aisling R.
    Liao, J. Xin
    Lopes, Vrishali V.
    LaPlante, Kerry L.
    Appaneal, Haley J.
    [J]. COVID, 2023, 3 (02): : 198 - 217
  • [32] JANSSEN COVID-19 VACCINE SAFETY IN A REAL-WORLD SETTING: A PHARMACOVIGILANCE STUDY
    Braga, A.
    Morais, Q. C.
    Da Costa, M.
    Santos, M.
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S182 - S182
  • [33] A Real-World Evidence Framework for Optimizing Dosing in All Patients with COVID-19
    Peck, Richard W.
    Weiner, Daniel
    Cook, Jack
    Robert Powell, J.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 108 (05) : 921 - 923
  • [34] Real-World Evidence: The Low Validity of Temperature Screening for COVID-19 Triage
    Pana, Bogdan C.
    Lopes, Henrique
    Furtunescu, Florentina
    Franco, Diogo
    Rapcea, Anca
    Stanca, Mihai
    Tanase, Alina
    Colita, Anca
    [J]. FRONTIERS IN PUBLIC HEALTH, 2021, 9
  • [35] Effectiveness and Safety of Enoxaparin Versus Unfractionated Heparin as Thromboprophylaxis in Hospitalized COVID-19 Patients: Real-World Evidence
    AlLehaibi, Lina H.
    Alomar, Mukhtar
    Almulhim, Abdulaziz
    Al-Makki, Sarah
    Alrwaili, Nazar R.
    Al-Bassam, Shahad
    Alsultan, Semat
    Al Saeed, Jenan
    Alsheef, Mohammad
    Abraham, Ivo
    Alamer, Ahmad
    [J]. ANNALS OF PHARMACOTHERAPY, 2023, 57 (04) : 361 - 374
  • [36] The Antiviral Effect of Nirmatrelvir/Ritonavir during COVID-19 Pandemic Real-World Data
    Petrakis, Vasilios
    Rafailidis, Petros
    Trypsianis, Grigorios
    Papazoglou, Dimitrios
    Panagopoulos, Periklis
    [J]. VIRUSES-BASEL, 2023, 15 (04):
  • [37] A real-world study of immune thrombocytopenia management during the COVID-19 pandemic in the UK
    Rampotas, Alexandros
    Watson, Edmund
    Burton, Kieran
    Hill, Quentin A.
    Pavord, Sue
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2022, 196 (02) : 351 - 355
  • [38] A systematic review of real-world contact tracing strategies at the onset of the COVID-19 pandemic
    Rosso, A.
    Amicosante, A. M. V.
    Mattioli, I.
    Bernardini, F.
    Guglielmi, E.
    Eugeni, E.
    Baglio, G.
    [J]. EUROPEAN JOURNAL OF PUBLIC HEALTH, 2023, 33
  • [39] IMPACT OF THE COVID-19 PANDEMIC ON REAL-WORLD ANTIPSYCHOTIC TREATMENT PATTERNS IN PATIENTS WITH SCHIZOPHRENIA
    Liu, Z.
    Patel, C. A.
    Campbell, A.
    Fu, A.
    Benson, C.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S484 - S484
  • [40] The impact of telemedicine on cancer care: real-world experience from a Peruvian institute during the COVID-19 pandemic
    Roque, Katia
    Ruiz, Rossana
    Otoya-Fernandez, Iris
    Galarreta, Jose
    Vidaurre, Tatiana
    Andrade de Mello, Ramon
    Neciosup, Silvia
    Mas, Luis
    Gomez, Henry
    [J]. FUTURE ONCOLOGY, 2022, 18 (31) : 3501 - 3508